JPM vs PSEC
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
JPM exhibits a concerning Piotroski F-Score of 2/9, indicating weak short-term fundamental health, and currently trades at a significant premium to both its Graham Number ($239.11) and Intrinsic Value ($140.07). While the company maintains a strong ROE of 16.13% and dominant market positioning, negative YoY earnings growth (-3.60%) and bearish insider activity from the CEO and CFO signal internal caution. The stock's current price of $313.68 suggests the market is pricing in a growth premium that is not currently supported by the deterministic health or value metrics.
PSEC exhibits significant financial distress as evidenced by a weak Piotroski F-Score of 2/9 and a bearish technical trend. While the stock trades at a deep discount to book value (P/B 0.45), this is offset by an unsustainable dividend payout ratio of 211.76% and negative profit margins. The combination of negative ROE and a current ratio below 1.0 suggests liquidity risks and poor capital efficiency. Despite short-term price momentum, the long-term trajectory and fundamental health indicators point to a 'yield trap' scenario.
Compare Another Pair
Related Comparisons
JPM vs PSEC: Head-to-Head Comparison
This page compares JPMorgan Chase & Co. (JPM) and Prospect Capital Corporation (PSEC) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.